A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Acmopatide (CT-868), a Fully Biased GLP-1/GIP Receptor Agonist, in Adults With Type 1 Diabetes and Overweight or Obesity
A experimental drug improved blood sugar and triggered significant weight loss in type 1 diabetes over four months without serious safety concerns.
This phase 2 multicenter randomized double-blind placebo-controlled trial examined A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Acmopatide (CT-868), a Fully Biased GLP-1/GIP Receptor Agonist, in Adults With Type 1 Diabetes and Overweight or Obesity. Acmopatide improved glycemic control and produced clinically meaningful weight loss without diabetic ketoacidosis or severe hypoglycemia over 16 weeks.
What the study was
- Study design
- Phase 2 multicenter randomized double-blind placebo-controlled trial
- Population
- Adults with type 1 diabetes and overweight or obesity
- Sample size
- 111 randomized participants
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Diabetes care
Why it surfaced
Phase 2 multicenter randomized double-blind placebo-controlled trial; Acmopatide improved glycemic control and produced clinically meaningful weight loss without diabetic ketoacidosis or severe hypoglycemia over 16 weeks. Score kept conservative because only the PubMed abstract and metadata were reviewed.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.